Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate-specific antigen screening in 2012

被引：62

作者：

Butler, Santino S. ^{[1
]}

Muralidhar, Vinayak ^{[1
]}

Zhao, Shuang G. ^{[2
]}

Sanford, Nina N. ^{[3
]}

Franco, Idalid ^{[1
]}

Fullerton, Zoe H. ^{[1
]}

Chavez, Janice ^{[1
]}

D'Amico, Anthony, V ^{[1
]}

Feng, Felix Y. ^{[4
]}

Rebbeck, Timothy R. ^{[1
,5
]}

Nguyen, Paul L. ^{[1
]}

Mahal, Brandon A. ^{[1
]}

机构：

[1] Harvard Med Sch, Dana Farber Canc Inst, Brigham & Womens Hosp, Boston, MA 02115 USA

[2] Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA

[3] Univ Texas Southwestern Med Ctr Dallas, Dept Radiat Oncol, Dallas, TX 75390 USA

[4] Univ Calif San Francisco, San Francisco, CA 94143 USA

[5] Harvard TH Chan Sch Publ Hlth, Boston, MA USA

来源：

CANCER | 2020年 / 126卷 / 04期

关键词：

prostatic neoplasms; PSA screening; incidence; prostate cancer; MORTALITY;

D O I：

10.1002/cncr.32604

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background We sought to determine the extent to which US Preventive Services Task Force (USPSTF) 2012 Grade D recommendations against prostate-specific antigen screening may have impacted recent prostate cancer disease incidence patterns in the United States across stage, National Comprehensive Cancer Network (NCCN) risk groups, and age groups. Methods SEER*Stat version 8.3.4 was used to calculate annual prostate cancer incidence rates from 2010 to 2015 for men aged >= 50 years according to American Joint Committee on Cancer stage at diagnosis (localized vs metastatic), NCCN risk group (low vs unfavorable [intermediate or high-risk]), and age group (50-74 years vs >= 75 years). Age-adjusted incidences per 100,000 persons with corresponding year-by-year incidence ratios (IRs) were calculated using the 2000 US Census population. Results From 2010 to 2015, the incidence (per 100,000 persons) of localized prostate cancer decreased from 195.4 to 131.9 (P-trend < .001) and from 189.0 to 123.4 (P-trend < .001) among men aged 50-74 and >= 75 years, respectively. The largest relative year-by-year decline occurred between 2011 and 2012 in NCCN low-risk disease (IR, 0.77 [0.75-0.79, P < .0001] and IR 0.68 [0.62-0.74, P < .0001] for men aged 50-74 and >= 75 years, respectively). From 2010-2015, the incidence of metastatic disease increased from 6.2 to 7.1 (P-trend < .001) and from 16.8 to 22.6 (P-trend < .001) among men aged 50-74 and >= 75 years, respectively. Conclusions This report illustrates recent prostate cancer "reverse migration" away from indolent disease and toward more aggressive disease beginning in 2012. The incidence of localized disease declined across age groups from 2012 to 2015, with the greatest relative declines occurring in low-risk disease. Additionally, the incidence of distant metastatic disease increased gradually throughout the study period.

引用

页码：717 / 724

页数：8

共 18 条

[1] Mortality Results from a Randomized Prostate-Cancer Screening Trial [J].

Andriole, Gerald L. ;

Grubb, Robert L., III ;

Buys, Saundra S. ;

Chia, David ;

Church, Timothy R. ;

Fouad, Mona N. ;

Gelmann, Edward P. ;

Kvale, Paul A. ;

Reding, Douglas J. ;

Weissfeld, Joel L. ;

Yokochi, Lance A. ;

Crawford, E. David ;

O'Brien, Barbara ;

Clapp, Jonathan D. ;

Rathmell, Joshua M. ;

Riley, Thomas L. ;

Hayes, Richard B. ;

Kramer, Barnett S. ;

Izmirlian, Grant ;

Miller, Anthony B. ;

Pinsky, Paul F. ;

Prorok, Philip C. ;

Gohagan, John K. ;

Berg, Christine D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (13) :1310-1319

[2] Lead times and overdetection due to prostate-specific antigen screening:: Estimates from the European randomized study of screening for prostate cancer [J].

Draisma, G ;

Boer, R ;

Otto, SJ ;

van der Cruijsen, IW ;

Damhuis, RAM ;

Schröder, FH ;

de Koning, HJ .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (12) :868-878

[3] Screening for Prostate Cancer US Preventive Services Task Force Recommendation Statement [J].

Grossman, David C. ;

Curry, Susan J. ;

Owens, Douglas K. ;

Bibbins-Domingo, Kirsten ;

Caughey, Aaron B. ;

Davidson, Karina W. ;

Doubeni, Chyke A. ;

Ebel, Mark ;

Epling, John W., Jr. ;

Kemper, Alex R. ;

Krist, Alex H. ;

Kubik, Martha ;

Landefeld, C. Seth ;

Mangione, Carol M. ;

Silverstein, Michael ;

Simon, Melissa A. ;

Siu, Albert L. ;

Tseng, Chien-Wen .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 319 (18) :1901-1913

[4] Increase in Prostate Cancer Distant Metastases at Diagnosis in the United States [J].

Hu, Jim C. ;

Nguyen, Paul ;

Mao, Jialin ;

Halpern, Joshua ;

Shoag, Jonathan ;

Wright, Jason D. ;

Sedrakyan, Art .

JAMA ONCOLOGY, 2017, 3 (05) :705-707

[5] Would prostate cancer detected by screening with prostate-specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population-based studies in Sweden [J].

Hugosson, J ;

Aus, G ;

Becker, C ;

Carlsson, S ;

Eriksson, H ;

Lilja, H ;

Lodding, P ;

Tibblin, G .

BJU INTERNATIONAL, 2000, 85 (09) :1078-1084

[6] Prostate Cancer Incidence Rates 2 Years After the US Preventive Services Task Force Recommendations Against Screening [J].

Jemal, Ahmedin ;

Ma, Jiemin ;

Siegel, Rebecca ;

Fedewa, Stacey ;

Brawley, Otis ;

Ward, Elizabeth M. .

JAMA ONCOLOGY, 2016, 2 (12) :1657-1660

[7] Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations [J].

Jemal, Ahmedin ;

Fedewa, Stacey A. ;

Ma, Jiemin ;

Siegel, Rebecca ;

Lin, Chun Chieh ;

Brawley, Otis ;

Ward, Elizabeth M. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 314 (19) :2054-2061

[8] Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement [J].

Moyer, Virginia A. .

ANNALS OF INTERNAL MEDICINE, 2012, 157 (02) :120-+

[9]

National Cancer Institute, SEER STAT DAT UNPUB

[10]

National Cancer Institute Surveillance Epidemiology and End Results Program, PSA VAL SEER DAT

← 1 2 →